A meta-analysis of flupentixol and melitracen tablets in the treatment of chronic obstructive pulmonary disease with anxiety and/or depression_West China Medical Journal

Authors：

ZHANG Xia ¹ ,  LIU Zhongyang ² , ZHANG Ling ¹ , GAO Junfeng ²

1. Postgraduate Training Base of the People’s Liberation Army Joint Service Support Force No.967 Hospital, Jinzhou Medical University, Dalian, Liaoning 116021, P. R. China;
2. Department of Respiratory Medicine, the People’s Liberation Army Joint Service Support Force No.967 Hospital Dalian, Liaoning 116021, P. R. China;

Corresponding author：

LIU Zhongyang, Email: 2030622263@qq.com

Keywords：

Chronic obstructive pulmonary disease; Flupentixol and melitracen tablets; Anxiety; Depression; Meta-analysis

DOI：

10.7507/1002-0179.201910052

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the clinical efficacy of flupentixol and melitracen tablets on the treatment of chronic obstructive pulmonary disease (COPD) with anxiety and/or depression.Methods Randomized controlled trials of flupentixol and melitracen tablets in the treatment of COPD with anxiety and/or depression were retrieved from PubMed, Sciencedirect Database, China National Knowledge Infrastructure, Wanfang Database, and CQVIP Journal Database, with retrieval time from January 2010 to December 2019. Two researchers screened literature and extracted data independently, and meta-analyzed the results using RevMan 5.3 software.Results A total of 9 articles with 1 123 patients were included. There were 567 patients in the trial group receiving flupentixol and melitracen tablets plus symptomatic support therapy and 556 patients in the control group receiving simple symptomatic treatment. After treatment, the Hamilton Anxiety Scale score [mean difference (MD)=−5.10, 95% confidence interval (CI) (−7.67, −2.54), P<0.000 1] and Hamilton Depression Scale score [MD=−3.94, 95%CI (−6.64, −1.23), P=0.004] in the trial group were lower than those in the control group, while the forced expiratory volume in one second as percentage of predicted volume [MD=4.89%, 95%CI (0.59%, 9.19%), P=0.03] and COPD Assessment Test score [MD=−3.21, 95%CI (−3.76, −2.66), P<0.000 01] in the trial group were better than those in the control group.Conclusion Flupentixol and melitracen tablets plus symptomatic support therapy has a better effect than simple symptomatic support treatment on COPD with anxiety and/or depression.

Citation： ZHANG Xia, LIU Zhongyang, ZHANG Ling, GAO Junfeng. A meta-analysis of flupentixol and melitracen tablets in the treatment of chronic obstructive pulmonary disease with anxiety and/or depression. West China Medical Journal, 2020, 35(1): 28-34. doi: 10.7507/1002-0179.201910052 Copy

1.	Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstrutive pulmonary disease. (2018-11-07)[2019-08-01]. https://goldcopd.org/archived-reports/.
2.	Agarwal A, Batra S, Prasad R, et al. A study on the prevalence of depression and the severity of depression in patients of chronic obstructive pulmonary disease in a semi-urban Indian population. Monaldi Arch Chest Dis, 2018, 88(1): 902.
3.	Safa M, Fallah Tafti S, Talischi F, et al. Severity of anxiety disorders in patients with chronic obstructive pulmonary disease. Iran J Psychiatry, 2015, 10(2): 128-132.
4.	丁静怡. 慢性阻塞性肺疾病合并焦虑抑郁的相关因素分析. 临床肺科杂志, 2018, 23(4): 690-693.
5.	中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南. 中华结核和呼吸杂志, 2002, 25(8): 453-460.
6.	中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2007 年修订版). 中华结核和呼吸杂志, 2007, 30(1): 8-17.
7.	中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013 年修订版). 中华结核和呼吸杂志, 2013, 36(4): 255-264.
8.	利桂河, 杨培文, 周妙玲, 等. 黛力新联合思力华治疗 COPD 稳定期疗效观察. 中国医学创新, 2012, 9(16): 129-130.
9.	张国伟, 吴绍娴, 许荻, 等. 黛力新治疗慢性阻塞性肺疾病加重期焦虑抑郁症. 航空航天医药, 2010, 21(7): 1092-1093.
10.	杨晓娟, 张自立, 杜永成. 氟哌噻吨美利曲辛对合并焦虑抑郁的慢性阻塞性肺疾病急性加重期患者治疗效果的研究. 中国药物与临床, 2014, 14(12): 1682-1684.
11.	王翔, 单洪武, 王东波. 氟哌噻吨美利曲辛辅助方案对 COPD 合并抑郁焦虑患者负面情绪、肺功能及生活质量的影响. 河北医药, 2016, 38(4): 540-542.
12.	罗建华, 李隆祥, 张英. 黛力新对绝经期女性稳定期 COPD 患者生活质量的影响. 中国现代医生, 2012, 50(13): 53-54, 57.
13.	罗麟洁, 范世明, 唐凤鸣, 等. 氟哌噻吨美利曲辛治疗 COPD 合并焦虑/抑郁患者的临床研究. 云南医药, 2016, 37(2): 146-150.
14.	邹志, 杨婵娟, 陈开容, 等. 抗焦虑抑郁辅助治疗对慢性阻塞性肺疾病患者临床疗效观察. 临床肺科杂志, 2016, 21(9): 1627-1631.
15.	郭欣, 李玉超, 刘震宇. 氟哌噻吨美利曲辛片对慢性阻塞性肺疾病合并焦虑抑郁症状患者的临床影响. 中国老年多器官疾病杂志, 2019, 18(7): 523-526.
16.	魏桂莲, 张泽丽. 黛力新联合奋乃静对合并焦虑抑郁的慢性阻塞性肺疾病急性加重患者治疗效果研究. 当代医学, 2018, 24(32): 104-106.
17.	Kyu HH, Abate D, Abate KH, et al. Global, regional, and National disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2018, 392(10159): 1859-1922.
18.	Flynn RWV, MacDonald TM, Chalmers JD, et al. The effect of changes to GOLD severity stage on long term morbidity and mortality in COPD. Respir Res, 2018, 19(1): 249.
19.	Martinez Rivera C, Costan Galicia J, Alcázar Navarrete B, et al. Factors associated with depression in COPD: a multicenter study. Lung, 2016, 194(3): 335-343.
20.	Underner M, Cuvelier A, Peiffer G, et al. The influence of anxiety and depression on COPD exacerbations. Rev Mal Respir, 2018, 35(6): 604-625.
21.	Aras YG, Tunç A, Güngen BD, et al. The effects of depression, anxiety and sleep disturbances on cognitive impairment in patients with chronic obstructive pulmonary disease. Cogn Neurodyn, 2017, 11(6): 565-571.
22.	Coventry PA, Bower P, Keyworth CA, et al. The effect of complex interventions on depression and anxiety in chronic obstructive pulmonary disease: systematic review and meta-analysis. PLoS One, 2013, 8(4): e60532.
23.	Smith S, Sonego S, Ketcheson L, et al. A review of the effectiveness of psychological interventions used for anxiety and depression in chronic obstructive pulmonary disease. BMJ Open Resp Res, 2014, 1(1): e000042.
24.	Heslop-Marshall K, Baker C, Carrick-Sen D, et al. Randomised controlled trial of cognitive behavioural therapy in COPD. ERJ Open Res, 2018, 4(4): 00094-2018.
25.	谢欲晓, 卢茜, 段亚景, 等. 肺康复的发展现状与展望. 华西医学, 2019, 34(5): 498-502.

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstrutive pulmonary disease. (2018-11-07)[2019-08-01]. https://goldcopd.org/archived-reports/.
2. Agarwal A, Batra S, Prasad R, et al. A study on the prevalence of depression and the severity of depression in patients of chronic obstructive pulmonary disease in a semi-urban Indian population. Monaldi Arch Chest Dis, 2018, 88(1): 902.
3. Safa M, Fallah Tafti S, Talischi F, et al. Severity of anxiety disorders in patients with chronic obstructive pulmonary disease. Iran J Psychiatry, 2015, 10(2): 128-132.
4. 丁静怡. 慢性阻塞性肺疾病合并焦虑抑郁的相关因素分析. 临床肺科杂志, 2018, 23(4): 690-693.
5. 中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南. 中华结核和呼吸杂志, 2002, 25(8): 453-460.
6. 中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2007 年修订版). 中华结核和呼吸杂志, 2007, 30(1): 8-17.
7. 中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013 年修订版). 中华结核和呼吸杂志, 2013, 36(4): 255-264.
8. 利桂河, 杨培文, 周妙玲, 等. 黛力新联合思力华治疗 COPD 稳定期疗效观察. 中国医学创新, 2012, 9(16): 129-130.
9. 张国伟, 吴绍娴, 许荻, 等. 黛力新治疗慢性阻塞性肺疾病加重期焦虑抑郁症. 航空航天医药, 2010, 21(7): 1092-1093.
10. 杨晓娟, 张自立, 杜永成. 氟哌噻吨美利曲辛对合并焦虑抑郁的慢性阻塞性肺疾病急性加重期患者治疗效果的研究. 中国药物与临床, 2014, 14(12): 1682-1684.
11. 王翔, 单洪武, 王东波. 氟哌噻吨美利曲辛辅助方案对 COPD 合并抑郁焦虑患者负面情绪、肺功能及生活质量的影响. 河北医药, 2016, 38(4): 540-542.
12. 罗建华, 李隆祥, 张英. 黛力新对绝经期女性稳定期 COPD 患者生活质量的影响. 中国现代医生, 2012, 50(13): 53-54, 57.
13. 罗麟洁, 范世明, 唐凤鸣, 等. 氟哌噻吨美利曲辛治疗 COPD 合并焦虑/抑郁患者的临床研究. 云南医药, 2016, 37(2): 146-150.
14. 邹志, 杨婵娟, 陈开容, 等. 抗焦虑抑郁辅助治疗对慢性阻塞性肺疾病患者临床疗效观察. 临床肺科杂志, 2016, 21(9): 1627-1631.
15. 郭欣, 李玉超, 刘震宇. 氟哌噻吨美利曲辛片对慢性阻塞性肺疾病合并焦虑抑郁症状患者的临床影响. 中国老年多器官疾病杂志, 2019, 18(7): 523-526.
16. 魏桂莲, 张泽丽. 黛力新联合奋乃静对合并焦虑抑郁的慢性阻塞性肺疾病急性加重患者治疗效果研究. 当代医学, 2018, 24(32): 104-106.
17. Kyu HH, Abate D, Abate KH, et al. Global, regional, and National disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2018, 392(10159): 1859-1922.
18. Flynn RWV, MacDonald TM, Chalmers JD, et al. The effect of changes to GOLD severity stage on long term morbidity and mortality in COPD. Respir Res, 2018, 19(1): 249.
19. Martinez Rivera C, Costan Galicia J, Alcázar Navarrete B, et al. Factors associated with depression in COPD: a multicenter study. Lung, 2016, 194(3): 335-343.
20. Underner M, Cuvelier A, Peiffer G, et al. The influence of anxiety and depression on COPD exacerbations. Rev Mal Respir, 2018, 35(6): 604-625.
21. Aras YG, Tunç A, Güngen BD, et al. The effects of depression, anxiety and sleep disturbances on cognitive impairment in patients with chronic obstructive pulmonary disease. Cogn Neurodyn, 2017, 11(6): 565-571.
22. Coventry PA, Bower P, Keyworth CA, et al. The effect of complex interventions on depression and anxiety in chronic obstructive pulmonary disease: systematic review and meta-analysis. PLoS One, 2013, 8(4): e60532.
23. Smith S, Sonego S, Ketcheson L, et al. A review of the effectiveness of psychological interventions used for anxiety and depression in chronic obstructive pulmonary disease. BMJ Open Resp Res, 2014, 1(1): e000042.
24. Heslop-Marshall K, Baker C, Carrick-Sen D, et al. Randomised controlled trial of cognitive behavioural therapy in COPD. ERJ Open Res, 2018, 4(4): 00094-2018.
25. 谢欲晓, 卢茜, 段亚景, 等. 肺康复的发展现状与展望. 华西医学, 2019, 34(5): 498-502.

West China Medical Journal

A meta-analysis of flupentixol and melitracen tablets in the treatment of chronic obstructive pulmonary disease with anxiety and/or depression

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content